Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0524 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0524 | DRUG | - |
Inclusion Criteria: * Person has had at least 2 years of seasonal allergies * Person has had a positive skin test to at least 1 of the allergens of the season * Person is a non-smoker Exclusion Criteria: * Person has been hospitalized within the last 4 weeks * Person is a female who has had a bab...
MK0524 is an investigational small molecule being studied for the treatment of seasonal allergies. It is currently in Phase 2 clinical development. The drug is being developed by Merck & Company, Inc. (NYSE: MRK).
MK0524 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 2 clinical development for seasonal allergies.
MK0524 is in Phase 2 clinical development. It has completed one Phase 2 clinical trial for seasonal allergies. The drug is investigational and has not been approved by regulatory authorities.
MK0524 has one completed Phase 2 clinical trial, identified as NCT00533208. This study, titled "MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)", enrolled 766 participants with seasonal allergies. The trial was randomized and double-blind.
MK0524 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for seasonal allergies. The drug has completed one clinical trial, but it remains under investigation and has not received regulatory approval.